Biotech
GC Therapeutics
GC Therapeutics raises $65M Series A at $280M valuation
$65M
Total Raised
Series A
Latest Round
2022
Founded
60+
Employees
Cambridge, MA
1 min read
Quick Facts
Valuation
$280M
Latest Round Size
$65M
Latest Round Date
November 2024
GC Therapeutics: Series A Funding Round
GC Therapeutics has successfully raised $65M in Series A funding, reaching a valuation of $280M.
Company Overview
Cell therapy-based medicine developer for cancer treatment
Funding Details
The Series A round was led by Arch Venture Partners, with participation from Venrock.
Company Information
- Headquarters: Cambridge, MA
- Founded: 2022
- Employees: 60+
- Category: Biotech
Investment
GC Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Arch Venture Partners: Verified investor in Series A
- Venrock: Verified investor in Series A
Key Investors
Arch Venture Partners
Lead Investor
Verified investor in Series A
Venrock
Investor
Verified investor in Series A
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M